Core Viewpoint - The stock of Insilico Medicine (03696) surged nearly 15% in early trading, reaching a high of HKD 54, which represents an increase of over 124% from its IPO price of HKD 24.05 [1] Group 1: Clinical Development - Insilico Medicine announced the completion of the first dosing of its innovative PHD inhibitor ISM5411 in a Phase IIa clinical trial named BETHESDA [1] - The candidate drug, developed with the company's proprietary generative AI platform Pharma.AI, is designed for the treatment of inflammatory bowel disease (IBD) and has recently received official approval for its generic name Garutadustat from the USAN Council [1] Group 2: Strategic Partnerships - On January 5, Insilico Medicine announced a multi-year collaboration with Sihuan Pharmaceutical for the development of anti-tumor drugs, with a total collaboration amount of USD 888 million [1] - Insilico Medicine is eligible to receive up to USD 32 million in upfront payments and milestone payments for recent research developments [1] - The company will utilize its self-developed AI platform Pharma.AI to focus on challenging targets in the anti-tumor field, identifying and developing new therapeutic drugs, while Sihuan will share the research costs and lead subsequent clinical validation and commercialization processes [1]
英矽智能早盘涨近15% 治疗炎症性肠病候选药物IIA期临床试验完成首例给药